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Abstract: Several gold(I) complexes with cysteine-containing 
dipeptides have been prepared starting from cystine by coupling 
different amino acids and using several orthogonal protections. The 
first step is the reaction of cystine, where the sulfur center is 
protected as disulfide, with Boc2O in order to protect the amino 
group, followed by coupling of an amino acid ester; finally the 
disulfide bridge is broken with mercaptoethanol to afford the 
dipeptide derivative. Further reaction with [AuCl(PPh3)] gives the 
gold-dipeptide-phosphine species. Starting from these formally 
gold(I) thiolate-dipeptide phosphine complexes with the general 
formula [Au(SR)(PR3)] different structural modifications, as change 
in the type of the amino protecting group, the type of phosphine, the 
number of gold(I) atoms per molecule, or the use of a non-
proteinogenic conformationally-restricted amino acid ester, were 
introduced in order to evaluate their influence in the biological 
activity of the final complexes. The cytotoxic activity in vitro of these 
complexes has been evaluated against different tumour human cell 
lines (A549, MiaPaca2 and Jurkat). The complexes show an 
outstanding cytotoxic activity with IC50 values in the very low 
micromolar range. Structure-Activity Relationships (SAR) observed 
from the complexes opens the possibility to the design of more 
potent and promising gold(I) anticancer agents. 
Introduction 
Metal-based drugs are an important class of compounds in 
medicinal chemistry employed clinically for the treatment of 
different diseases.1 Cisplatin and the following generations of 
platinum based drugs are among the most widely used 
chemotherapeutic agents.2 However their effectiveness is still 
restricted by several clinical problems, such as a limited 
spectrum of activity, development of resistance and undesired 
toxic side-effects. The use of different metal compounds with 
different biological properties and targets has emerged as an 
alternative strategy to overcome these limitations. 
Gold compounds have been employed since last century for the 
treatment of rheumatoid arthritis and in the last decades some 
gold(I) and gold(III) complexes with promising biological 
activities as anticancer, antimicrobial, fungicidal, anti-HIV, or in 
the treatment of asthma or parasitic diseases, among others, 
have been prepared.3 In addition, the mechanistic studies 
showed that, in general DNA is not the main target and 
interactions with several enzimes,4 and more specifically the 
seleno-enzime thioredoxine reductase,5 proteasome,6 kinases,7 
among others have been reported as a mode to finally lead to 
apoptosis through a mitochondrial pathway. 
Diverse approaches have been used to prepare gold(I) and 
gold(III) drugs. For gold(I) the synthesis has been focused on 
the use of auranofin analogues8 or the coordination to gold of 
several ligands mainly  phosphines,9 and carbenes.10 For 
gold(III), cyclometallated complexes or coordination to the 
metallic centre of bypiridine, dithiocarbamate or porphyrin 
ligands have been successfully employed in order to prepare 
new anticancer gold drugs.11  
Surprisingly and in spite of the great number of reported gold 
complexes which show activity in the biological systems, the 
number of gold species with biomolecules such as amino acids 
and peptides is very scarce. Peptide research on drug design 
and drug discovery is one of the most promising fields in the 
development of new drugs. Peptide sequences are constituents 
of larger proteins, where they are responsible for molecular 
recognition and biological activities.12  
There are only a few reports of reactions of gold(I) and mainly 
gold(III) with amino acids such as cysteine and methionine.13 
Gold(I) peptides with the cysteine-modified neuropeptide 
encephalin14 and by gold(I) azide cycloaddition reactions with 
alkynyl peptides have been reported by Metzler-Nolte and 
coworkers.15 The latter type of compounds has shown to 
overcome cisplatin resistance in a p53-mutant cancer cell line. 
The crystal structure of a gold(I) complex with the human 
glutathione reductase16 and also a gold protein with the AuPEt3 
fragment bonded to a histidine rest17 have been reported, and 
could give interesting insights in the biological function of gold 
compounds. We have previously reported in the synthesis and 
functionalisation of gold(I)-phosphine-nicotinic acid thiolate with 
amino acids providing complexes with very good cytotoxic 
activity.18 Additionally, gold(III) peptide derivatives with histidine 
residues,19 and dithiocarbamate functionalised dipeptides have 
also been described.20 
In this context and with the aim of preparing more active and 
selective gold drugs, we propose the formation of gold(I) 
complexes with dipeptides. The introduction of peptides in the 
complexes might decrease the undesired toxic side-effects (they 
are biocompatible ligands) and they could serve as good carriers 
to deliver the gold atom to the biological target.21 A major 
problem for cancer chemotherapeutics is crossing the cell 
membranes, and a strategy to overcome this is to make use of 
the peptide-based delivery systems, which can transport small 
peptides and peptide-like drugs to the cells. These peptide 
transporters over-express receptors in some types of tumours, 
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these could be target by the gold-peptide compounds providing 
then with more internalization and subsequent selectivity.20  
 
Here we report on an efficient and general method to prepare 
dipeptides containing a cysteine moiety and different 
proteinogenic amino acids, using different orthogonal protections. 
The coordination of these dipeptides to a gold(I) phosphine 
fragment gives novel and stable gold-peptide bioconjugates, 
which cytototoxic activity has been studied. Several structural 
modifications of this peptide-gold-phosphine symptom have 
been performed in order to know which factor could improve 
their activity. Consequently, changes in the phosphine ligand, 
the amino protecting group, the number of coordinated AuPPh3+ 
units, or other modifications, such as the introduction of a 
conformationally-restricted non-proteinogenic amino acid (Oic) in 
the peptide have been performed. 
Cytotoxic activity in vitro against different tumour cell lines has 
been analysed, showing outstanding cytotoxicity in all cases with 
IC50 values in the very low micromolar range. 
Results and Discussion 
Synthesis and characterization  
 
Gold(I) dipeptide phosphine complexes. In our aim of 
preparing gold complexes with cysteine-containing dipeptides 
we though in using as precursor the previously described 
complex Ac-Cys(AuPPh3)-OH, in which there is an acid moiety 
that could couple with other amino acid esters, in a similar 
manner as we have reported earlier for the gold-phosphine 
complexes with the nicotinic acid thiolate.18a However, the 
preparation of the desired complexes was not possible by this 
route, probably because of solubility reasons. Then, a new 
synthetic strategy was selected, which consist on the use of 
commercially available cystine with the use of different 
orthogonal protecting groups for each functional unit (amino, 
carboxylic acid and thiol) of the dipeptide.22 
In the cystine the sulfur atom is already protected as disulfide, 
and then the first step consisted on the protection of the amino 
group, using the Boc (tert-butoxy carbonyl) protecting group 
according to previously described conditions (Scheme 1). The 
success of the reaction was easily confirmed by 1H NMR, whose 
spectrum shows the appearance of the signals corresponding to 
the Boc group at  = 6.79 (carbamate proton) and 1.36 ppm 
(alkyl protons). The following step is the coupling of the amino 
acid ester through the free carboxylic acid of (Boc-Cys-OH)2 
through standard solution peptide chemistry (employing PyBOP 
as activating agent and DIPEA as base), and subsequent flash 
chromatography yielded 1a-6a derivatives in good yields. Six 
proteinogenic amino acid esters from glycine, alanine, valine, 
phenylalanine, methionine or proline were selected to prepare 
the dipeptide ligands. Each amino acid differs in the side chain 
group, what determines properties as lipophilicity, polarity, 
reactivity or steric hindrance, and could have influence in the 
exchange reactions that are supposed to give the final 
complexes with other biomolecules in the organism, affecting to 
the final activity, selectivity or biodistribution of the complex.  
.  
Scheme 1. Synthesis of the gold(I) dipeptide complexes 1-6. 
As common features, the 1H and 13C-NMR NMR spectra of 
compounds 1a-5a show, in addition to all the expected 
resonances for the molecule, the signals belonging to the new 
amide bond in the range  = 8.16-7.40 ppm and  = 170.5-169.2 
ppm, respectively. Compound 6a appears as a mixture of 
rotamers (ratio 1:0.2) as consequence as the conformationally-
restricted structure of proline, which possesses a five-membered 
ring (pyrrolidine) in its structure, giving a more complex 
spectrum. Selective reduction of the disulfides of 1a-6a 
employing a strong reducing thiol (-mercaptoethanol)23 in soft 
basic media (DIPEA) afforded the desired dipeptide thiol ligands 
1b-6b. Six different dipeptides containing cysteine groups have 
been prepared according to the synthetic route showed in 
Scheme 1: Boc-Cys-Gly-OMe (1b), Boc-Cys-Ala-OMe (2b), Boc-
Cys-Val-OMe (3b), Boc-Cys-Phe-OMe (4b), Boc-Cys-Met-OMe 
(5b) and Boc-Cys-Pro-OMe (6b). The 1H-NMR spectra present 
the resonance for the thiol group as a doublet of doublets or as a 
multiplet in the range  = 1.46-1.90 ppm, while the resonances 
corresponding to C protons appear each one with a 
characteristic shape as a doublets of doublets of doublets 
(diastereotopic protons). The IR spectra also present the 
absorption bands corresponding to the thiol group in the range 
2562-2580 cm-1 as weak bands. The dipeptides  1b-6b are 
valuable ligands that easily react with [AuCl(PPh3)] employing 
K2CO3 as a base, to give the desired complexes 1-6 in high 
yields after chromatographic purification. Complexes 1-6, just as 
all the complexes reported in this work, were fully characterized 
by 1H, 13C and 31P NMR spectroscopy, IR spectroscopy and MS 
spectrometry. The 1H NMR spectra show the resonances 
corresponding to the dipeptide and triphenylphosphine protons. 
The proton for the thiol group has desappeared, which agrees 
with coordination of the sulfur to gold affording the desired 
complexes. Remarkably, as a common feature, the resonances 
of the C protons (diastereotopic protons) are simplified and 
each one appears as a doublet of doublets at  = 3.60 and  = 
3.25 ppm, approximately, strongly downfield shifted related to 






the starting dipeptide. The 31P{1H} NMR spectra present an 
unique resonance for all of the complexes in the range of 36-38 
ppm, which agree with similar gold(I) complexes, with thiolates 
and phosphines as ligands, previously reported, and are 3-5 
ppm downfield shifted related to the starting gold(I) complex. 
The 13C{1H} NMR APT spectra show the resonances for the 
dipeptide and triphenylphosphine moieties. Again, the signals 
belonging to C appear downfield shifted after complex 
formation (in the range of 30-35 ppm). The assignment of the 
resonances was made with the 1H-13C HSQC and 1H-13C HMBC 
experiments. The IR spectra present, among others, the 
absorptions for the amide, ester and aromatic unit and also the 
disappearance of the absorptions for the thiol group. The mass 
spectra (HRMS ESI+) presents for all the compounds the 
molecular peak [M+Na]+ and [M+H]+. The different gold(I) 
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Figure 1. Gold(I) dipeptide complexes 1-6 
Structural modifications. The structure of complexes 1-6 
described above, allows the introduction of several structural 
modifications with the purpose of obtaining information on how 
the changes in the structure affect the biological properties of 
the complexes, and thus can stablish a structure activity 
relationship (SAR), and can obtain compounds with better 
activity, selectivity and pharmaceutical profile. The selected 
structural modifications performed were the following: a) type of 
phosphine (7), b) type of amino protecting group (8), c) coupling 
of a non-proteinogenic conformationally restricted amino acid 
ester (9), and d) charge and number of gold atoms per molecule 
(10-11). All of these modifications could have influence in 
changing the polarity, electronic or steric properties of the 
complex, activity or selectivity and others as biodistribution or 
reactivity towards other biomolecules in the organism of the final 
complex. The different modifications carried out are summarized 
in Figure 2. 
 
Figure 2. Structural modifications introduced in the complexes 
a) Preparation of the complex with a different phosphine 
ligand (7). The phosphine PPh2Py was selected to prepare the 
analogous to complex 1. Because the type of phosphine 
coordinated to gold(I) has a great influence in the activity of the 
final complex, determining factors as reactivity, behaviour in 
exchange reactions or biodistribution, the change for the related 
phosphine with a pyridine moiety PPh2Py was employed as 
ancillary ligand, which could bind further to other metals, interact 
with other biomolecules or alter the lipophilicity of the complex. 
Reaction of Boc-Cys(H)-Gly-OMe 1b with [AuCl(PPh2Py)] 
afforded complex 7 in high yield after chromatographic 
purification (Scheme 2).  
 
Scheme 2. Synthesis of complex 7  
The 1H and 13C{1H}NMR spectra show the expected resonances 
from all the protons and carbon atoms, that are essentially the 
same observed for the analogous complex 1, and will not be 
discussed further here. The only exception are the signals 
belong to the pyridine, for which a correct assignment could be 
done by the realization of 2D-NMR experiments (1H-1H COSY, 
1H-13C HSQC and 1H-13C HMBC) since these resonances and 
those of the phenyl rings appear at similar chemical shift. Again, 
the 31P{1H} NMR spectra present a unique resonance 
corresponding to the phosphorus of the 2-diphenylphosphino 
pyridine ligand, the chemical shift is observed at 37.0 ppm, a 
value similar to that observed for 1. IR and MS data agree with 
the proposed structure. 
b) Preparation of the complex with different amino 
protecting group (8). Boc (tert-butoxycarbonyl) was employed 
as the amino protecting group in the preparation of the 
complexes 1-6. In this case, the Z (benzyloxycarbonyl) group 
was selected in order to evaluate how this change affects the 
biologic activity. Although in both cases the amino group is 
protected as a carbamate, the change introduced could affect to 






the polarity or exchange reactions with other biomolecules in the 
organism, important for the activity and selectivity of the drug. 
The [Au(Z-Cys-Gly-OMe)(PPh3)] complex 8 was prepared 
following a similar synthetic route to that used in the preparation 
of complexes 1-6 (Scheme 3).  
 
Scheme 3. Synthesis of complex 8  
Again, orthogonal protection of the different functional groups in 
the molecule was necessary. In the first place, starting from the 
disulphide 1a, cleavage of Boc amino protecting group was 
carried out employing standard conditions by reaction with 3M 
HCl/AcOEt solution. Introduction of the Z protecting group was 
successfully achieved by reaction with a convenient source as 
Z-Cl, employing DIPEA as a base and DMAP as catalyst. The 
intermediate 8b was obtained in moderate yield after 
chromatographic purification. Discussion of spectroscopic data 
(1H and 13C-NMR spectra) is similar to described previously for 
his analogue 1b with the exception of the signals belonging to 
the benzyl group instead of the tert-butyl as can be found in the 
experimental section. Disulfide reduction was carried out in the 
same way as described above. Again, the 1H-NMR spectrum of 
dipeptide 8c shows, as the most remarkable features, the 
appearance of the signal of the thiol group at  = 1.70 ppm as a 
doublet of doublets and the diastereotopic C protons appears 
each one with the characteristic shape as a doublet of doublet of 
doublets. The IR spectrum clearly shows a band corresponding 
to the absorption of the SH group at 2579 cm-1. The last step 
consisted in the deprotonation of the thiol and coordination of 
the corresponding thiolate to the gold(I) center as described 
above to give the desired complex 8 in pure form and high yield. 
Complex 8 is also analogous to 1 and consequently in the 
spectroscopic data the same features are observed: the 1H-NMR 
spectrum shows the disappearance of the thiol proton and the 
C protons resonance appears downfield shifted and with a 
more simplified shape. In the 13C-NMR spectrum the signal 
belonging to C is also shifted downfield, and in the IR spectrum 
the thiol band also disappears after the formation of the complex, 
which agrees with the proposed structure. 
c) Preparation of the complex with different coupled amino 
acid ester (9). The type of amino acid ester has influence in the 
ability of the carrier to deliver the gold(I) to its target. In fact, in a 
previous work we observed that functionalisation with proline 
usually gives better cytotoxic complexes compared with other 
amino acids.18b In this case, we decided to couple to the cystine 
derivative the octahydroindole amino acid ester (Oic), a non-
proteinogenic bicyclic proline analogue.24 This amino acid has 
been employed in the design of peptides with interesting 
pharmaceutical profiles, mainly because conformationally 
restricted amino acids help to fix conformations and have 
influence in the interactions with receptors in the organism. 
Moreover, the dipeptides containing this moiety could present a 
higher resistance to hydrolysis by diverse enzymes. For all of 
these reasons, the preparation of a complex bearing this moiety 
is expected to improve the activity and selectivity. The synthetic 
route employed to prepare the complex 9 is shown in the 
Scheme 4.   
 
Scheme 4. Synthesis of complex 7  
As can be observed, this synthetic route is essentially the same 
as described previously for the preparation of the dipeptide 
complexes 1-6 and will not be further discussed here. In this 
case, the coupling of another amino ester type was carried out. 
Similarly to complex 6 bearing the proline moiety, complex 9 
appears as a mixture of rotamers in the NMR spectra. This 
complex possesses a high number of protons and carbon atoms, 
many of them showing similar chemical shifts. Nevertheless, all 
the signals could be correctly assigned by the realization of 2D-
NMR experiments (1H-1H COSY, 1H-13C HSQC and 1H-13C 
HMBC). 
d) Preparation of the complexes with more number of gold 
atoms per molecule (10 and 11). Diverse studies indicate that 
in gold(I) complexes with thiolates and phosphines as ligands, 
the cytotoxicity is due mainly to the metallic centre, whereas the 
phosphine ligand allow the gold(I) atom to cross the cell-
membranes and the thiolate takes part in exchange ligand 
reactions with other biomolecules. Keeping in mind this, it is 
logical to think that adding more gold(I) atoms per molecule the 
cytotoxicity of the complex will increase, as we observed 
previously.18b Moreover, nowadays there is a strong interest in 
the synthesis of lipophilic and cationic compounds which seem 
to be able to cross cell-membranes and selectively accumulate 
in mitochondria,25 just where it seems that gold(I) complexes 
exert their therapheutic effect, by inhibiting diverse enzymes as 
for example Thioredoxin Reductase (TrX). Moreover, further 
coordination of gold(I) atoms to sulfur could have a strong 






influence in the transference reactions of the metal to other 
biomolecules, determining its transport, biodistribution or 
enzyme-inhibition ability. For all of these reasons, we carried out 
the synthesis of the dinuclear (10) and trinuclear (11) cationic 
complexes derived from the mononuclear complex 1 by reaction 
with the high electrophilic complex [Au(OTf)(PPh3)] generated in 
situ (Scheme 5).  
 
Scheme 5. Synthesis of the dinuclear (10) and trinuclear (11) complexes 
derived from 1. i)  [Au(OTf)(PPh3), ii) 2 [Au(OTf)(PPh3).   
Remarkably, the 1H NMR spectrum of complex 11 appears as a 
mixture of rotamers in contrast with complexes 1 and 10, 
probably due to more steric hindrance. In all the cases we 
observed the expected resonances for the protons belonging to 
the dipeptide and triphenylphosphine. In the 1H NMR spectra of 
complexes 10 and 11, the carbamate and amide protons, and all 
the protons belonging to the dipeptide appear more downfield 
shifted than observed for complex 1. Integration of aromatic 
protons corresponding to triphenylphosphine ligands also 
confirms the coordination of additional gold(I) triphenylphosphine 
moieties. The 19F-NMR spectra show a single signal at  = - 77,8 
ppm that belongs to the triflate counter anion in both cases. 
However, the most notable feature is the chemical shift for the 
phosphorus atoms in the 31P NMR NMR spectra, that appears at 
 = 33.2 ppm (dinuclear complex) and  = 32.3 ppm (trinuclear 
complex), that are strongly upfield shifted (4 and 5 ppm, 
respectively) compared with 1. The mass spectra (ESI+) 
presents the molecular peak [M]+. 
  
Cytotoxic activity. The cytototoxic of complexes 1-11 was 
tested against three different human tumour cell lines: Jurkat (T-
cell leukaemia), MiaPaca2 (pancreatic carcinoma) and A549 
(lung carcinoma), compared to the results with cisplatin. 
Compounds 1-11 are not soluble in water, but they are soluble in 
DMSO and in the DMSO/water mixtures used in the tests, which 
contain a small amount of DMSO. We did not observe any 
precipitation of the complexes or metallic gold while performing 
the tests. Their colourless d6-DMSO solutions are very stable at 
room temperature, as shown in the 1H NMR spectra in which the 
signals remain the same for weeks. Cells were exposed to 
different concentrations of each compound for a total of 24 h. 
Using the colorimetric MTT viability assay, (MTT = 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide), the IC50 
values (final concentration < 0.5 % DMSO) were calculated from 
dose–response curves obtained by non-linear regression 
analysis. IC50 values are concentrations of a drug required to 
inhibit tumour cell proliferation by 50%, compared to the control 
cells treated with DMSO alone. The IC50 values for complexes 1-
11 are collected in Table 1. These values can be compared with 
those reported for Cisplatin dissolved in water: IC50 at 24 h in 
A549, MiaPaca2 and Jurkat cells are 114.2 µM, 76.5 µM and 
10.8 µM, respectively.26 
 
Table 1. IC50 (M) (24 h), with standard deviations, of complexes against A549. 
MiaPaca2 and Jurkat  
 
COMPLEX A549 MiaPaca2 Jurkat 
1 1.5 ± 0.2 2.0 ± 0.2 0.9 ± 0.1 
2 1.9 ± 0.1 1.9 ± 0.1 1.6 ± 0.1 
3 2.3 ± 0.1 3.0 ± 0.1 2.2 ± 0.1 
4 15.6 ± 0.11 5.4 ± 0.1 0.4 ± 0.1 
5 4.8  ±  0.1 1.8  ± 0.1 1.7 ± 0.1 
6 3.0 ± 0.1 0.7 ± 0.1 0.5 ± 0.1 
7 5.0 ± 0.2 0.5 ± 0.1 0.8 ± 0.1 
8 2.7 ± 0.1 1.5 ± 0.1 1.1 ± 0.1 
9 2.1 ± 0.1  1.2 ± 0.1 1.5 ± 0.1 
10 1.8 ± 0.1 0.1 ± 0.1 0.6 ± 0.1 
11 3.5 ± 0.1 1.5 ± 0.1 0.8 ± 0.1 
 
All the synthesized complexes were active against all the 
different tumour cell lines in very low concentrations (low 
micromolar range). Complexes 1-11 exhibit excellent 
antiproliferative activities, with IC50 values ranging from 1.5 to 
15.6 M in A549 cells, 0.4 to 2.2 M in Jurkat cells, and 0.1 to 
5.4 M in MiaPaca2. The Jurkat and MiaPaca2 cell lines were 
the most sensitive to our compounds, whereas A549 showed 
more resistance to the complexes.  
The gold(I) dipeptide complexes (1-6) displayed very good 
cytotoxicity in all the tumour cell lines. The type of the 
proteinogenic amino ester coupled to cysteine has some 
influence in the cytotoxicity of the final complex: the complexes 
which incorporate glycine or proline in their structure showed the 
best IC50 values. The change of the type of phosphine ligand 
coordinated to gold(I) (complex 7), the amino protecting group 
(complex 8) or the amino acid ester coupled to cysteine 
(complex 9) led to more potent complexes in the MiaPaca2 
tumour cell line, although in the A549 resulted in a decrease of 
the cytotoxicity of the complex in comparison with the related 
complex 1. The coordination of an additional [AuPPh3]+ fragment 






(complex 10) to 1 has a strong influence in the cytotoxicity, 
mainly in the MiaPaca2 and Jurkat tumour cell lines. In particular, 
complex 10 was the most potent of all the series. Surprisingly, 
coordination of two additional [AuPPh3]+ fragments (complex 11) 
to 1 did not improve the potency of the complex. Then, the use 
of a dipeptide containing glycine or proline, or the coordination of 
two gold(I) centres to the sulfur atom, giving a cationic complex, 
yielded the most potent cytotoxic complexes.  
Comparison of the activity of this family of gold-peptide 
derivatives with the anticancer drug cisplatin, shows that these 
complexes displayed much more in vitro cytotoxic activity. In 
relation with other gold(I)-peptide species our complexes have 
much lower IC50  values, although comparison with the same cell 
lines is not possible. The activity is also higher than in the 
gold(I)-nicotinic acid thiolate functionalised with amino acids 
previously described by us.14b Nevertheless the very low values 
obtained in these complexes in resistant cell lines as A549 and 
MiaPaca2 measured after 24 h represent outstanding values, 
which made them as very promising metallo-drugs candidates in 
order to continue their evaluation and mechanism studies . 
 
Conclusions 
A series of gold(I) complexes with cysteine-containing dipeptides 
have been prepared starting from cystine by coupling different 
amino acids, and using several orthogonal protections. In these 
molecules the gold centre is coordinated directly to the dipeptide, 
to the sulfur of the cysteine as thiolate. These novel derivatives 
with biologically relevant molecules could deliver the gold centre 
selectively to the tumour cells because they can act as 
peptidomimetics and target peptide delivery systems, which 
have over-expressed receptors in tumour cells. 
In this formally gold(I) thiolate-dipeptide phosphine complexes 
with the general formula [Au(SR)(PR3)] different structural 
modifications as change in the type of the amino protecting 
group, the type of phosphine, the number of AuPPh3+ fragment 
coordinated to the sulfur centre, or the use of non-proteinogenic 
conformationally-restricted amino acid ester in the peptide, were 
introduced in order to evaluate their influence in the biological 
activity of the final complexes. The cytotoxic activity in vitro of 
these complexes has been evaluated against different tumour 
human cell lines (A549, MiaPaca2 and Jurkat). The complexes 
show excellent cytotoxic activity with IC50 values in the very low 
micromolar range, as low as 0.1 M. The structural changes 
performed in the parent compound have led to the synthesis of 
the most effective compound in all the cell lines, which is the 
complex with two AuPPh3+ fragments coordinated to the Boc-
Cys-Gly-OMe peptide. 
Experimental Section 
Experimental Details. Instrumentation. C, H, and N analysis were 
carried out with a PERKIN-ELMER 2400 microanalyzer. Mass spectra 
were recorded on a BRUKER ESQUIRE 3000 PLUS, with the 
electrospray (ESI) technique and on a BRUKER MICROFLEX (MALDI-
TOF). 1H, 13C{H}, 31P{H} and 19F NMR, including 2D experiments, were 
recorded at room temperature on a BRUKER AVANCE 400 spectrometer 
(1H, 400 MHz, 13C, 100.6 MHz) or on a BRUKER AVANCE II 300 
spectrometer (1H, 300 MHz, 13C, 75.5 MHz), with chemical shifts (δ, ppm) 
reported relative to the solvent peaks of the deuterated solvent.21  
Starting Materials. [AuCl(PPh3)] and [AuCl(PPh2Py)] were prepared 
according to published procedures. All other reagents were commercially 
available. Solvents were used as received without purification or drying. 
Synthesis of compounds 
General Procedure for coupling amino acid esters. Synthesis of 
compounds 1a-6a and 9a (Procedure A). To a solution of (Boc-Cys-
OH)2 (1 mmol) in anhydrous DMF (5 mL) was added the corresponding 
amino ester hydrochloride (2.4 mmol), PyBOP (2.2 mmol) and DIPEA 
(6.6 mmol). The mixture was stirred for 48 h under argon atmosphere at 
room temperature. Then, the resultant clear solution was diluted with 
AcOEt (100 ml) and washed with water (5 x 60 ml). The organic phase 
was dried over anhydrous MgSO4, filtered off and evaporated to dryness. 
The crude of the reaction was purified by column chromatography on 
silica gel using as eluent a mixture of ethyl acetate/hexane (1:1). 
General Procedure for reducing disulfides to thiols. Synthesis of 
compounds 1b-6b, 8c and 9b (Procedure B). To a solution of the 
corresponding disulfide (Boc-Cys-aa-OMe)2 (1 mmol) in dry CH2Cl2 (50 
ml), -mercaptoethanol (4 mmol) and DIPEA (4 mmol) were added. The 
mixture was stirred for 48 h under argon atmosphere at room 
temperature. Then, the solvent was evaporated under reduced pressure 
and the crude of reaction redissolved in AcOEt (100 ml) and washed with 
an aqueous saturated solution of KHSO4 (3 x 40 ml) and a saturated 
aqueous solution of NaCl (3 x 40 ml). The organic phase was dried over 
anhydrous MgSO4, filtered off and evaporated to dryness. The crude of 
the reaction was purified by column chromatography on silica gel using 
as eluent a mixture of acetone/hexane (1:1). 
General Procedure for the Synthesis of gold(I) dipeptide complexes 
1-9 (Procedure C). To a solution of the corresponding dipeptide 
derivative Boc-Cys-aa-OMe (1 mmol) in acetone (10 ml) an excess of 
K2CO3 (2 mmol) was added. The mixture was stirred for 5 min. Then, 
[AuCl(PPh3)] or [AuCl(PPh2Py)] (1 mmol) in acetone (10 ml) was added 
and the reaction mixture was stirred at room temperature for 24 h. After 
this time, the reaction mixture was filtered over celite and the clear 
solution evaporated under reduced pressure. Complexes 1-9 were 
purified by column chromatography of silica gel using as eluent a mixture 
of AcOEt/hexane (1:1). 
(Boc-Cys-OH)2: To a 10% (w/w) K2CO3 in water (70 ml) solution cystine 
(4.47 g, 18.6 mmol) was added. Then, a solution of Boc2O (10.2 g, 46.7 
mmol) in THF (60 ml) was added. The mixture was stirred for 24 h under 
reflux (80º C), and after, diluted with water (120 ml). Carefully 
acidification by adding dropwise an aqueous saturated solution of KHSO4 
was carried out to a soft acidic media (pH = 3-4). The white precipitate 
observed was extracted with CHCl3 (3x50 ml). The organic phases were 
collected, dried over anhydrous MgSO4, filtered off and evaporated, 
affording a white solid (7.78 g, 17.7 mmol, yield = 95.0 %) which was 
employed without further purification. 1H NMR (d6-DMSO, 300 MHz, 
(ppm), J (Hz)): 6.79 (d, 2H, J = 6.6, CONHCys), 4.15 (m, 2H, C,CysH), 
3.29 and 2.78 (m and dd, 4H, diastereotopic protons, J = 13.5 and 9.0, 
C,CysH2) and 1.36 (s, 18H, CBocH3). 13C NMR (d6-DMSO, 300 MHz, 
(ppm), J (Hz)): 172.7 (COOH), 155.1 (CONHCys), 78.2 (C, CBoc), 53.0 
(C,CysH), 39.4 (C,CysH2) and 28.2 (CBocH3). MS ESI(+) m/z: [M+Na]+ = 






463.1 (calcd), 463.0 (found). IR(cm-1): 3400-3100 (br, COOH), 3384 (br, 
w, CONH), 1682 (s, COOH), 1654 (s, OCONH), 1159 and 1104 (s, C-O), 
614 (s, S-S).  
(Boc-Cys-Gly-OMe)2 (1a): The reaction of (Boc-Cys-OH)2 (1.32 g, 3 
mmol), HCl·H-Gly-OMe (0.904 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) 
and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 1a (1.517 g, 2.6 mmol) as a white solid (Yield = 
86.8 %). 1H NMR (CDCl3, 400 MHz, (ppm), J (Hz)): 8.16 (m, 2H, 
CONHGly), 5.55 (d, 2H, J = 9.6, CONHCys), 4.94 (“dt”, 2H, J = 9.9 and 3.4, 
CCysH), 4.15 and 3.91 (dd and dd, ABX system, 4H, diastereotopic 
protons, J = 18.0 and 6.4 and J = 17.6 and 5.6, CGlyH2), 3.72 (s, 6H, 
OCH3), 3.07 and 2,92 (dd and dd, ABM system, diastereotopic protons, 
4H, J = 14.8 and 4.0 and J = 14.4 and 10.8, C,CysH2) and 1.42 (s, 18H, 
CBocH3). 13C NMR (CDCl3, 400 MHz, d(ppm), J (Hz)): 170.8 (COOMe), 
169.7 (CONHGly), 155.9 (CONHCys), 80.3 (C, CBoc), 54.5 (CCysH), 52.2 
(OCH3), 46.8 (C,GlyH2), 40.9 (C,CysH2) and 28.3 (CBocH3). MS ESI(+) 
m/z: [M+Na]+ = 605.2 (calcd.), 605.1 (found). IR (cm-1): 3410 (br, CONH), 
3330 (br, OCONH), 1750 (s, COOMe), 1689 (s, OCONH), 1660 (s, 
CONH) 1227 and 1162 (s, C-O), 615 (s, S-S). TLC Rf: 0.3 
(AcOEt/hexane 1:1).
(Boc-Cys-Ala-OMe)2 (2a): The reaction of (Boc-Cys-OH)2 (1.32 g, 3 
mmol), HCl·H-Ala-OMe (1.004 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) 
and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 2a (1.545 g, 2.5 mmol) as a white solid (Yield = 
84.3 %). 1H NMR (CDCl3, 400 MHz, (ppm), J (Hz)): 7.84 (d, 2H, J = 8.0, 
CONHAla), 5.51 (d, 2H, J = 9.6, CONHCys), 4.88 (“dt”, 2H, J = 10.5 and 
3.4, C,CysH), 4.63 (“q”, 2H, J = 7.2, C,AlaH), 3.70 (s, 6H, OCH3), 3.08 
and 2.88 (dd and dd, ABM system, 4H, diastereotopic protons, J = 14.4 
and 4.0 and J = 14.4 and 11.2, C,CysH2), 1.46 (d, 6H, J = 6.4, C,AlaH3) 
and 1.45 (s, 18H, CBocH3). 13C NMR (CDCl3, 400 MHz, (ppm), J (Hz)): 
172.7 (COOMe), 170.2 (CONHAla), 155.8 (CONHCys), 80.0 (C, CBoc), 54.2 
(C,CysH),  52.3 (OCH3), 47.8 (C,AlaH), 47.1 (C,CysH2), 28.2 (CBocH3) and 
17.4 (C,AlaH3). MS ESI(+) m/z: [M+Na]+ = 633.2 (clcd), 633.1 (found). 
IR(cm-1): 3417 (br, CONH), 3350 (br, OCONH), 1751 (s, OCONH), 1662 
(s, CONH), 1168 and 1138 (s, C-O), 607 (s, S-S). TLC Rf: 0.3 
(AcOEt/hexane 1:1). 
(Boc-Cys-Val-OMe)2 (3a): The reaction of (Boc-Cys-OH)2 (1.32 g, 3 
mmol), HCl·H-Val-OMe (1.207 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) 
and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 3a (1.634 g, 2.4 mmol) as a white solid (Yield = 
81.7 %). 1H NMR (CDCl3, 400 MHz, (ppm), J (Hz)): 7.40 (d, 2H, J = 7.2, 
CONHVal), 5.56 (d, 2H, J = 8.8, CONHCys), 4.71 (m, 2H, C,CysH), 4.48 (dd, 
2H, J = 8.8 and 6.4, C,ValH), 3.72 (s, 6H, OCH3), 3.04 (m, 4H, 
diastereotopic protons, C,CysH2), 2.18 (m, 2H, C,ValH), 1.46 (s, 18H, 
CBocH3) and 0.97 and 0.95 (d, 12H, J = 4.4 and 4.4, C,ValH3). 13C NMR 
(CDCl3, 400 MHz, (ppm), J (Hz)): 172.0 (COOMe), 170.4 (CONHVal), 
155.6 (CONHCys), 80.3 (C, CBoc), 57.8 (C,ValH), 54.0 (C,CysH), 52.1 
(OCH3), 44.8 (C,CysH2), 30.8 (C,ValH), 28.3 (CBocH3) and 19.2 and 18.4 
(C,ValH3). MS ESI(+) m/z: [M+Na]+ = 689.3 (calcd.), 689.2 (found). IR 
(cm-1): 3330 (br, CONH and OCONH), 1740 (s, COOMe), 1683 (s, 
OCONH), 1662 (s, CONH), 1160 and 1136 (s, C-O), 632 (s, S-S). TLC 
Rf: 0.3 (AcOEt/hexane 1:1). 
(Boc-Cys-Phe-OMe)2 (4a): The reaction of (Boc-Cys-OH)2 (1.32 g, 3 
mmol), HCl·H-Phe-OMe (1.553 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) 
and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 4a (1.822 g, 2.4 mmol) as a white solid (Yield = 
79.6 %). 1H NMR (CDCl3, 300 MHz, (ppm), J (Hz)): 7.67 (d, 2H, J = 8.0, 
CONHPhe), 7.14 (m, 10H, ArPhe), 5.38 (d, 2H, J = 9.2, CONHCys), 4.78 
(“dt”, 2H, J = 8.3 and 6.2, C,PheH), 4.68 (m, 2H, C,CysH), 3.60 (s, 6H, 
OCH3), 3.15 and 2.98 (dd and m, ABM system, 4H, diastereotopic 
protons, J = 13.6 and 6.0, C,PheH2), 2.94 and 2.83 (m and dd, ABM 
system, 2H, diastereotopic protons, J = 14.4 and 10.0, C,CysH2) and 1.38 
(s, 18H, CBocH3). 13C NMR (CDCl3, 300 MHz, (ppm), J (Hz)): 170.6 
(COOMe), 169.2 (CONHPhe), 154.6 (CONHCys), 135.2 (C, C1Ar), 128.1 
(CH, C3Ar), 127.5 (CH, C2Ar), 126.0 (CH, C4Ar), 79,2 (C, CBoc), 53.2 
(C,CysH), 52.6 (CPheH), 51.3 (OCH3), 45.0 (CCysH2), 36.8 (C,PheH2) and 
27.3 (CBocH3,). MS ESI(+) m/z: [M+Na]+ = 785.3 (calcd), 785.2 (found). 
IR(cm-1): 3332 (br, CONH and OCONH), 1738 (s, COOMe), 1690 (s, 
OCONH), 1683 (s, CONH), 1515 and 1436 (w, Ar), 1164 (s, C-O), 748 
and 697 (w, Ar), 619 (s, S-S). TLC Rf: 0.3 (AcOEt/hexane 1:1). 
(Boc-Cys-Met-OMe)2 (5a): The reaction of (Boc-Cys-OH)2 (1.32 g, 3 
mmol), HCl·H-Met-OMe (1.438 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) 
and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 5a (1.599 g, 2.2 mmol) as a white solid (Yield = 
72.9 %). 1H NMR  (CDCl3, 300 MHz, ppm), J (Hz)): 7.77 (d, 2H, J = 8.1, 
CONHMet), 5.53 (d, 2H, J = 9.6, CONHCys), 4.84 (m, 2H, C,CysH), 4.75 
(“dt”, 2H, J = 8.8 and 5.3, CMetH), 3.72 (s, 6H, OCH3), 3.09 and 2.91 (dd, 
ABM system, 4H, diastereotopic protons, J = 14.7 and 4.2 and J = 14.1 
and 10.2, C,cysH2), 2.56 (m, 4H, C,MetH2), 2.22 and 1.95 (m, 4H, 
diastereotopic protons, CMetH2), 2.10 (s, 6H, SCH3) and 1.46 (s, 18H, 
CBocH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 171.9 (COOMe), 
170.5 (CONHMet), 155.8 (CONHCys), 80.2 (C, CBoc), 54.3 (C,CysH), 52.4 
(OCH3), 51.4 (C,MetH), 46.6 (C,CysH2), 31.2 (C,MetH), 30.5 (C,MetH), 28.3 
(CBocH3) and 15.4 (SCH3). MS ESI(+) m/z: [M+Na]+ = 753.2 (calcd), 753.1 
(found). IR(cm-1): 3329 (br, CONH and OCONH), 1739 (s, COOMe), 
1688 (s, OCONH), 1665 (s, CONH), 1165 (s, C-O), 634 (s, S-S). TLC Rf: 
0.3 (AcOEt/hexane 1:1). 
(Boc-Cys-Pro-OMe)2 (6a): The reaction of (Boc-Cys-OH)2 (1.32 g, 3 
mmol), HCl·H-Pro-OMe (1.438 g, 7.2 mmol), PyBOP (3.43 g, 6.6 mmol) 
and DIPEA (3.39 ml, 19.8 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 6a (1.405 g, 2.1 mmol) as a white solid (Yield = 
70.7 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): rotamers mixture 
(ratio: 1: 0,2) : 5.33 (d, 2H, J = 8.7, CONHCys), 4.78 (m, 2H, C,CysH), 4.53 
(dd, 2H, J = 8.6 and 4.2 CProH), 3.76 (m, 4H, C,ProH2), 3.74 (A) and 3.71 
(B) (s, 6H, OCH3), 3.10 and 2.93 (dd and m, ABM system, diastereotopic 
protons, 4H, J = 13.8 and 5.1, C,CysH2), 2.20 (m, 4H, diastereotopic 
protons, C,ProH2), 2.02 (m, 4H, C,ProH2) and 1.42 (s, 18H, CBocH3). 13C 
NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 172.1 (COOMe), 169.5 
(CONPro), 155.3 (CONHCys), 80.0 (C, CBoc), 59.4 (B) and 58.9 (A) 
(C,ProH), 52.8 (B) and 52.2 (A) (OCH3), 51.6 (B) and 51.4 (A) (C,CysH), 
47.0 (A) and 46,6 (B) (C,ProH2), 42.0 (B) and 41.5 (A) (C,CysH2), 31.1 (B) 
and 29.0 (A) (C,ProH2), 28.3 (CBocH3) and 24.8 (A) and 22.2 (B) (C,ProH2). 
MS ESI(+) m/z: [M+Na]+ = 685.2 (calcd), 685.1 (found). IR(cm-1): 3299 
(br, OCONH), 1741 (s, COOMe), 1706 (s, OCONH), 1639 (s, CONH), 
1161 (s, C-O), 658 (s, S-S). TLC Rf: 0.3 (AcOEt/hexane 1:1). 
Boc-Cys-Gly-OMe (1b): The reaction of 1a (0.234 g, 0.5 mmol), -
mercaptoethanol (0.140 ml, 2 mmol) and DIPEA (0.34 ml, 2 mmol) 
following the Procedure B, afforded 1b (0.218 g, 0.75 mmol) as a white 
solid (Yield = 74.6 %). 1H NMR (CDCl3, 400 MHz,  (ppm), J (Hz)): 6.74 
(m, 1H, CONHGly), 5.40 (m, 1H, CONHCys), 4.35 (m, 1H, C,CysH), 4.05 
and 3.95 (dd, ABX system, 2H, diastereotopic protons, J = 18.0 and 5.6 
and J = 18.4 and 5.2, C,GlyH2), 3.77 (s, 3H, OCH3), 3.19 and 2.70 (ddd, 
ABMN system, 2H, diastereotopic protons, J = 16.4, 10.8 and 5.6 and J = 
16.4, 10.8 and 5.6, C,CysH2), 1.68 (dd, 1H, J = 10.8 and 7.2, SH) and 
1.47 (s, 9H, CBocH3). 13C NMR (CDCl3, 400 MHz,  (ppm), J (Hz)): 170.5 
(COOMe), 169.9 (CONHGly), 155.4 (CONHCys), 80.7 (C, CBoc), 55.4 
(C,CysH), 52.4 (OCH3), 41.2 (C,GlyH2), 28.2 (CBocH3) and 27.0 (C,CysH2). 
MS ESI(+) m/z: [M+Na]+ = 315.1 (calcd), 315.0 (found). IR(cm-1): 3315 (br, 
CONH and OCONH), 2574 (w, SH), 1744 (s, COOMe), 1684 (s, 
OCONH), 1654 (s, CONH), 1161 and 1036 (s, C-O). TLC Rf: 0.5 
(acetone/hexane 1:1).  






Boc-Cys-Ala-OMe (2b): The reaction of 2a (1.054 g, 1.72 mmol), -
mercaptoethanol (0.484 ml, 6.9 mmol) and DIPEA (1.18 ml, 6.9 mmol) 
following the Procedure B, afforded 2b (0.759 g, 2.48 mmol) as a white 
solid (Yield = 72.1 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 6.84 
(d, 1H, J = 6.6, CONHAla), 5.45 (d, 1H, J = 5.7, CONHCys), 4.56 (“q”, 1H, J 
= 7.2, C,AlaH), 4.34 (m, 1H, C,CysH), 3.75 (s, 3H, OCH3), 3.08 and 2.72 
(ddd, ABMN system, 2H, diastereotopic protons, J = 13.8, 7.9 and 4.4 
and J = 13.9, 10.1 and 6.2, CCysH2), 1.68 (dd, 1H, J = 17.7 and 8.7, SH), 
1.46 (s, 9H, CBocH3) and 1.42 (d, 3H, J = 7.2, C,AlaH3). 13C NMR (CDCl3, 
300 MHz,  (ppm), J (Hz)): 172.9 (COOMe), 169.6 (CONHAla), 155.3 
(CONHCys), 80.6 (C, CBoc), 55.5 (C,CysH), 52.5 (OCH3), 48.3 (CAlaH3), 
28.2 (CBocH3), 27.0 (C,CysH2) and 18.2 (C,AlaH3). MS ESI(+) m/z: 
[M+Na]+ = 329.1 (calcd), 329.0 (found). IR (cm-1): 3312 (br, CONH and 
OCONH), 2576 (w, SH), 1748 (s, COOMe), 1683 (s, OCONH), 1655 (s, 
CONH), 1160 (s, C-O). TLC Rf: 0.5 (acetone/hexane 1:1).   
Boc-Cys-Val-OMe (3b): The reaction of 3a (1.024 g, 1.54 mmol), -
mercaptoethanol (0.431 ml, 6.1 mmol) and DIPEA (1.052 ml, 6.1 mmol) 
following the Procedure B, afforded 3b (0.799 g, 2.39 mmol) as a white 
solid (Yield = 77.8 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 6.81 
(d, 1H, J = 7.8, CONHVal), 5.46 (d, 1H, J = 5.7, CONHCys), 4.51 (dd, 1H, J 
= 8.7 and 4.8, C,ValH), 4.34 (dd, 1H, J = 11.5 and 7.0, C,CysH), 3.74 (s, 
3H, OCH3), 3.10 and 2.72 (ddd, ABMN system, 2H, diastereotopic 
protons, J = 13.8, 7.8 and 4.3 and J = 13.9, 10.2 and 6.3, C,CysH2), 2.19 
(m, 1H, C,ValH), 1.69 (m, 1H, SH), 1.46 (s, 9H, CBocH3) and 0.94 and 
0.91 (d, 6H, diastereotopic protons, J = 6.9 and J = 6.9, C,ValH3). 13C 
NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 171.9 (COOMe), 170.1 
(CONHVal), 155.5 (CONHCys), 80.7 (C, CBoc), 57.3 (C,ValH), 55.4 (C,CysH), 
52.2 (OCH3), 31.1 (C,ValH), 28.2 (CBocH3), 26.6 (C,CysH2) and 19.0 and 
17.7 (C,ValH). MS ESI(+) m/z: [M+Na]+ = 357.1 (calcd), 357.0 (found). 
IR(cm-1): 3310 (br, CONH and OCONH), 2556 (w, SH), 1747 (s, COOMe), 
1681 (s, OCONH), 1646 (s, CONH), 1160 (s, C-O). TLC Rf: 0.5 
(acetone/hexane 1:1). 
Boc-Cys-Phe-OMe (4b): The reaction of 4a (0.417 g, 0.547 mmol), -
mercaptoethanol (0.154 ml, 2.19 mmol) and DIPEA (0.375 ml, 2.19 
mmol) following the Procedure B, afforded 4b (0.258 g, 0.675 mmol) as a 
white solid (Yield = 77.8 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
7.21 (m, 5H, Ar), 6.68 (d, 1H, J = 9.0, CONHPhe), 5.33 (m, 1H, CONHCys), 
4.87 (dd, 1H, J = 13.8 and 6.4, C,PheH), 4.31 (m, 1H, C,CysH), 3.73 (s, 
3H, OCH3), 3.19 and 3,09 (dd, ABM system, 2H, diastereotopic protons, 
J = 14.1 and 5.7 and J = 8.4 and 3.0, C,PheH2), 3.04 and 2.64 (m and 
ddd, ABMN system, 2H, diastereotopic protons, J = 13.9, 10.5 and 6.0, 
CCysH2), 1.46 (m, 1H, SH) and 1.45 (s, 9H, CBocH3). 13C NMR (CDCl3, 
300 MHz,  (ppm), J (Hz)): 171.5 (COOMe), 169.6 (CONHPhe), 154.6 
(CONHCys), 135.6 (C, C1Ar), 129.2 (CH, C3Ar), 128.7 (CH, C2Ar), 127.2 
(CH, C4Ar), 80.9 (C, CBoc), 55.4 (C,CysH), 53.3 (CPheH), 52.6 (OCH3), 
37.9 (C,PheH2), 28.2 (CBocH3) and 26.9 (C,CysH2). MS ESI(+) m/z: 
[M+Na]+ = 405.1 (clcd), 405.0 (found). IR(cm-1): 3336 (br, CONH and 
OCONH), 2562 (w, SH), 1739 (s, COOMe), 1648 (s, CONH and 
OCONH), 1544, 1518 and 1456 (w, Ar), 1160 (s, C-O). TLC Rf: 0.5 
(acetone/hexane 1:1). 
Boc-Cys-Met-OMe (5b) : The reaction of 5a (0.789 g, 1.08 mmol), -
mercaptoethanol (0.303 ml, 4.32 mmol) and DIPEA (0.740 ml, 4.32 
mmol) following the Procedure B, afforded 5b (0.541 g, 1.48 mmol) as a 
white solid (Yield = 68.5 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
6.97 (d, 1H, J = 7.8, CONHMet), 5.43 (m, 1H, CONHCys), 4.84 (m, 1H, 
C,CysH), 4.70 (“dt”, 1H, J = 7.6 and 5.0 C,MetH), 3.76 (s, 3H, OCH3), 3.12 
and 2.72 (ddd, ABMN system, 2H, diastereotopic protons, J = 13.9, 7.8 
and 4.3 and J = 13.9, 10.2 and 6.1, C,CysH2), 2.51 (“t”, 2H, J = 7.4, 
C,MetH2), 2.20 and 2.01 (m, 2H, diastereotopic protons, C,MetH2), 2.09 (s, 
3H, SCH3), 1.67 (m, 1H, SH) and 1.47 (s, 9H, CBocH3). 13C NMR (CDCl3, 
300 MHz,  (ppm), J (Hz)): 171.9 (COOMe), 169.9 (CONHMet), 152.0 
(CONHCys), 80.8 (C, CBoc), 55.4 (C,CysH), 52.6 (OCH3), 51.7 (CMetH), 
31.3 (C,MetH), 30.5 (C,MetH), 28.3 (CBocH3,), 26.8 (C,CysH2) and 15.4 
(SCH3). MS ESI(+) m/z: [M+Na]+ = 389.1 (calcd), 389.0 (found). IR(cm-1): 
3280 (br, CONH and OCONH), 2580 (w, SH), 1735 (s, COOMe), 1674 (s, 
OCONH), 1660 (s, CONH) and 1160 (s, C-O). TLC Rf: 0.5 
(acetone/hexane 1:1). 
Boc-Cys-Pro-OMe (6b): The reaction of 6a (1.530 g, 2.29 mmol), -
mercaptoethanol (0.65 ml, 9.24 mmol) and DIPEA (1.582 ml, 9.24 mmol) 
following the Procedure B, afforded 6b (0.795 g, 2.39 mmol) as a white 
solid (Yield = 52.2 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
rotamers mixture (ratio 1: 0.1) : 5.41 (d, 1H, J = 8.7, CONHCys), 4.77 (B) 
and 4.67(A) (dd, 1H, J = 7.5 and 2.7 and J = 13.8 and 6.9, C,CysH), 4.53 
(A) and 4.41 (B) (dd and m, 1H, J = 8.4 and 4.8, C,ProH), 3.86 (m, 2H, 
C,ProH2), 3.75 (B) and 3.73 (A) (s, 3H, OCH3), 2.83 (m, ABMN system, 
2H, diastereotopic protons, C,CysH2), 2.23 (m, 2H, diastereotopic protons, 
C,ProH2), 2.02 (m, diastereotopic protons, 2H, C,ProH2), 1.90 (“t”, J = 9.0, 
SH) and 1.43 (s, 9H, CBocH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J 
(Hz)): 172.3 (COOMe), 169.3 (CONPro), 155.1 (CONHCys), 80.0 (C, CBoc), 
59.6 (B) and 58.9 (A) (C,ProH), 53.4 (C,CysH), 52.3 (OCH3), 47.3 (A) and 
46.5 (B) (C,ProH2), 31.1 (B) and 29.0 (A) (C,ProH2), 28.3 (CBocH3), 27.4 
(C,CysH2), 24.9 (A) and 22.3 (B) (C,ProH2). MS ESI(+) m/z: [M+Na]+ = 
355.1 (calcd), 355.0 (found). IR(cm-1): 3327 (br, CONH and OCONH), 
2580 (w, SH), 1742 (s, COOMe), 1679 (s, OCONH), 1641 (s, CONH), 
1160 (s, C-O). TLC Rf: 0.5 (acetone/hexane 1:1). 
Boc-Cys(AuPPh3)-Gly-OMe (1): The reaction of 1b (0.291 g, 1 mmol), 
[AuCl(PPh3)] (0.495 g, 1 mmol) and K2CO3 (0.276 g, 2 mmol) following 
the Procedure C, afforded 1 (0.709 g, 0.944 mmol) as a white solid (Yield 
= 94.6 %). 1H NMR (CDCl3, 400 MHz,  (ppm), J (Hz)): 7.51 (m, 15H, Ar), 
7.27 (m, 1H, CONHGly), 5.90 (m, 1H, CONHCys), 4.38 (m, 1H, C,CysH), 
3.94 and 3.76 (dd, ABX system, 2H, diastereotopic protons, J = 18.4 and 
5.2 and J = 18.4 and 4.4, C,GlyH2), 3.65 (s, 3H, OCH3), 3.61 and 3.24 (m 
and dd, ABM system, 2H, diastereotopic protons, J = 12.8 and 6.4, 
C,CysH2) and 1.42 (s, 9H, CBocH3). 13C NMR (CDCl3, 400 MHz,  (ppm), J 
(Hz)): 171.7 (COOMe), 170.0 (CONHGly), 155.6 (CONHCys), 134.3 (d, CH, 
J = 13.8, C2), 131.7 (CH, C4), 129.4 (d, C, J = 57.7, C1), 129.2 (d, CH, J 
= 11.6, C3), 79.8 (C, CBoc), 57.9 (C,CysH), 52.2 (OCH3), 41.2 (C,GlyH2), 
30.7 (C,CysH2) and 28.3 (CBocH3). 31P NMR (CDCl3, 400 MHz,  (ppm)): 
37.1. MS ESI(+) m/z: [M+Na]+ = 773.1 (calcd), 773.2 (found). Elemental 
analysis found (%): C, 46.48; H, 4.66; N, 3.75; S, 4.42; calcd. for 
C29H34AuN2O5PS:  C, 46.40; H, 4.57; N, 3.73; S, 4.27. IR(cm-1): 3321 (br, 
CONH and OCONH), 1751 (s, COOMe), 1706 (s, OCONH), 1665 (s, 
CONH), 1479 and 1434 (w, Ar), 1160 and 1099 (s, C-O) and 746, 709 
and 690 (w, Ar). TLC Rf: 0.5 (AcOEt/hexane 1:1). 
Boc-Cys(AuPPh3)-Ala-OMe (2): The reaction of 2b (0.640 g, 2.09 mmol), 
[AuCl(PPh3)] (1.033 g, 2.09 mmol) and K2CO3 (0.577 g, 4.18 mmol) 
following the Procedure C, afforded 2 (1.288 g, 1.69 mmol) as a white 
solid (Yield = 80.6 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 7.53 
(m, 15H, Ar), 7.36 (m, 1H, CONHAla), 5.86 (m, 1H, CONHCys), 4.51 (“q”, 
1H, J = 7.2, C,AlaH), 4.35 (m, 1H, C,CysH), 3.71 (s, 3H, OCH3), 3.62 and 
3.27 (dd, ABM system, 2H, diastereotopic protons, J = 13.2 and 4.5 and 
J = 13.2 and 6.3, C,CysH2), 1.44 (s, 9H, CBocH3) and 1.28 (d, 3H, J = 7.2, 
C,AlaH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 173.0 (COOMe), 
171.0 (CONHAla), 155.5 (CONHCys), 134.2 (d, CH, J = 13.9, C2), 131.7 (d, 
CH, J = 2.4, C4), 129.4 (d, C, J = 58.1, C1), 129.2 (d, CH, J = 11.6, C3), 
57.9 (C,CysH), 52.2 (OCH3), 48.2 (C,AlaH), 30.5 (C,CysH2), 28.3 (CBocH3) 
and 18.6 (C,AlaH3). 31P NMR (CDCl3, 300 MHz,  (ppm)): 36.5. MS 
ESI(+) m/z: [M+Na]+ = 787.1 (calcd), 787.0 (found). Elemental analysis 
found (%): C, 47.16; H, 4.85; N, 3.76; S, 4.23; calcd. for 
C30H36AuN2O5PS:  C, 47.12; H, 4.75; N, 3.66; S, 4.19. IR(cm-1): 3314 (br, 
CONH and OCONH), 1738 (s, COOMe), 1707 (s, OCONH), 1666 (s, 






CONH), 1480, 1452 and 1435 (w, Ar), 1157 and 1099 (s, C-O) and 746, 
709 and 690 (w, Ar). TLC Rf: 0.5 (AcOEt/hexane 1:1). 
Boc-Cys(AuPPh3)-Val-OMe (3): The reaction of 3b (0.662 g, 1.97 mmol), 
[AuCl(PPh3)] (0.977 g, 1.97 mmol) and K2CO3 (0.544 g, 3.94 mmol) 
following the Procedure C, afforded 3 (1.185 g, 1.50 mmol) as a white 
solid (Yield = 75.9 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 7.53 
(m, 15H, Ar), 7.27 (m, 1H, CONHVal), 5.85 (m, 1H, CONHCys), 4.49 (dd, 
1H, J = 8.7 and 5.1, C,ValH), 4.35 (m, 1H, C,CysH), 3.71 (s, 3H, OCH3), 
3.57 and 3,29 (dd, ABM system, 2H, diastereotopic protons, J = 12.9 and 
4.8 and J = 12.9 and 6.6, C,CysH2), 2.15 (m, 1H, C,ValH), 1.43 (s, 9H, 
CBocH3) and 0.90 (d, 3H, J = 7.2, C,ValH3) and 0.88 (d, 3H, J = 6.9, 
C,ValH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 171.9 (COOMe), 
171.4 (CONHVal), 155.5 (CONHCys), 134.2 (d, CH, J = 13.8, C2), 131.8 (d, 
CH, J = 2.4, C4), 129.2 (d, C, J = 59.2, C1), 129.2 (d, C, J = 11.6, C3), 
58.6 (C,ValH2), 57.4 (C,CysH), 51.9 (OCH3), 31.3 (C,ValH), 30.4 (C,CysH2), 
28.3 (CBocH3,) and 19.0 (C,ValH3) and 18.1 (C,ValH3). 31P NMR (CDCl3, 
300 MHz,  (ppm)): 36.0. MS ESI(+) m/z: [M+Na]+ = 815.2 (calcd), 815.1 
(found). Elemental analysis found (%): C, 48.58; H, 5.14; N, 3.57; S, 
4.10; calcd. for C32H40AuN2O5PS:  C, 48.49; H, 5.09; N, 3.53; S, 4.05. 
IR(cm-1): 3329 (br, CONH and OCONH), 1738 (s, COOMe), 1707 (s, 
OCONH), 1669 (s, CONH), 1479 and 1434 (w, Ar), 1157 and 1099 (s, C-
O) and 745, 709 and 690 (w, Ar). TLC Rf: 0.5 (AcOEt/hexane 1:1). 
Boc-Cys(AuPPh3)-Phe-OMe (4): The reaction of 4b (0.208 g, 1.54 
mmol), [AuCl(PPh3)] (0.269 g, 0.54 mmol) and K2CO3 (0.149 g, 1.08 
mmol) following the Procedure C, afforded 4 (0.294 g, 0.35 mmol) as a 
white solid (Yield = 64.7 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
7.49 (m, 15H, Ar), 7.29 (m, 1H, CONHPhe), 7.16 (m, 5H, ArPhe), 5.81 (m, 
1H, CONHCys), 4.80 (“td”, 1H, J = 7.7 and 5.6, C,PheH), 4.32 (m, 1H, 
C,CysH), 3.62 (s, 3H, OCH3), 3.57 and 3.25 (dd, ABM system, 2H, 
diastereotopic protons, J = 13.2 and 6.3, C,CysH2), 3.01 and 2.94 (dd, 
ABM system, 2H, diastereotopic protons, J = 13.8 and 6.0 and J = 13.8 
and 5.4, C,PheH2) and 1.25 (s, 9H, CBocH3). 13C NMR (CDCl3, 300 MHz,  
(ppm), J (Hz)): 171.4 (COOMe), 171.0 (CONHPhe), 155.5 (CONHCys), 
136.0 (C, C5Phe), 134.2 (d, CH, J = 13.8, C2), 131.7 (d, CH, J = 2.4, C4), 
129.5 (CH, C7Phe), 129.3 (d, C, J = 58.6, C1), 129.2 (d, CH, J = 11.6, C3), 
128.4 (CH, C6Phe), 126.9 (CH, C8Phe), 58.1 (C,PheH2), 53.4 (C,CysH), 
52.0 (OCH3), 38.3 (C,PheH2), 29.7 (C,CysH2) and 28.2 (CBocH3). 31P NMR 
(CDCl3, 300 MHz,  (ppm)): 36.2. MS ESI(+) m/z: [M+Na]+ = 863.2 
(calcd), 863.2 (found). Elemental analysis found (%): C, 51.50; H, 4.88; N, 
3.36; S, 3.88; calcd. for C36H40AuN2O5PS:  C, 51.43; H, 4.80; N, 3.33; S, 
3.81. IR(cm-1): 3329 (br, CONH and OCONH), 1741 (s, COOMe), 1708 (s, 
OCONH), 1669 (s, CONH), 1480 and 1435 (w, Ar), 1098 and 1017 (s, C-
O) and 798, 745, 709 and 690 (w, Ar). TLC Rf: 0.5 (AcOEt/hexane 1:1). 
Boc-Cys(AuPPh3)-Met-OMe (5): The reaction of 5b (0.423 g, 1.16 
mmol), [AuCl(PPh3)] (0.572 g, 1.16 mmol) and K2CO3 (0.319 g, 2.31 
mmol) following the Procedure C, afforded 5 (0.599 g, 0.73 mmol) as a 
white solid (Yield = 62.8 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
7.50 (m, 15H, Ar), 7.46 (m, 1H, CONHMet), 5.81 (d, 1H, J = 5.1, CONHCys), 
4.64 (“dt”, 1H, J = 7.4 and 5.1, C,MetH), 4.33 (dd, 1H, J = 10.5 and 5.5, 
C,CysH), 3.71 (s, 3H, OCH3), 3.56 and 3.25 (dd, ABM system, 2H, 
diastereotopic protons, J = 12.9 and 5.1 and J = 13.2 and 6.6, C,CysH2), 
2.48 (ddd, 2H, J = 8.0, 6.7 and 1.5, C,MetH2), 2.12 and 1.93 (m, 2H, 
diastereotopic protons, C,MetH2), 2.01 (s, 3H, SCH3) and 1.41 (s, 9H, 
CBocH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 172.0 (COOMe), 
171.3 (CONHMet), 155.5 (CONHCys), 134.3 (d, CH, J = 14.0, C2), 131.5 
(CH, C4), 129.7 (d, C, J = 54.7, C1), 129.2 (d, CH, J = 11.3, C3), 80.4 (C, 
CBoc), 58.1 (C,CysH), 52.4 (OCH3), 51.7 (C,MetH), 31.7 (CMetH2), 30.4 
(C,MetH2), 29.9 (C,CysH2), 28.3 (CBocH3,) and 15.4 (SCH3). 31P NMR 
(CDCl3, 300 MHz,  (ppm)): 37.6. HRMS MS ESI(+) m/z: [M+Na]+ = 
847.1674 (calcd), 847.1694 (found). Elemental analysis found (%): C, 
46.67; H, 4.94; N, 3.44; S, 7.81; calcd. for C32H40AuN2O5PS2:  C, 46.60; 
H, 4.89; N, 3.40; S, 7.78. IR(cm-1): 3320 (br, CONH and OCONH), 1736 
(s, COOMe), 1706 (s, OCONH), 1667 (s, CONH), 1479 and 1434 (w, Ar), 
1160 and 1099 (s, C-O) and 797, 746, 709 and 691 (w, Ar). TLC Rf: 0.5 
(AcOEt/hexane 1:1). 
Boc-Cys(AuPPh3)-Pro-OMe (6): The reaction of 6b (0.658 g, 1.98 
mmol), [AuCl(PPh3)] (0.98 g, 1.98 mmol) and K2CO3 (0.547 g, 3.96 
mmol) following the Procedure C, afforded 6 (1.052 g, 1.33 mmol) as a 
white solid (Yield = 67.2 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
rotamers mixture (ratio 1:0.36): 7.51 (m, 15H, Ar), 5.53 (B) and 4.52 (A) 
(dd, 1H, J = 7.5 and 6.3 and J = 8.1 and 3.6, C,ProH), 5.34 (d, 1H, J = 7.5, 
CONHCys), 4.46 (m, 1H, C,CysH), 3.75-3.70 (m, 2H, C,ProH2), 3.65 (A) 
and 3.58 (B) (s, 3H, OCH3), 3.41 and 3.11 (dd, ABM system, 2H, 
diastereotopic protons, J = 13.5 and 4.5 and J = 13.5 and 9.3, C,CysH2), 
2.15 and 2.04 (m, 2H, diastereotopic protons, C,ProH2), 1.91 (m, 2H, 
C,ProH2) and 1.44 (B) and 1.40 (A) (s, 9H, CBocH3). 13C NMR (CDCl3, 300 
MHz,  (ppm), J (Hz)): rotamers mixture: 170.7 (COOMe), 156.3 
(CONHCys), 134.2 (d, CH, J = 13.7, C2), 131.7 (d, CH, J = 2.4, C4), 129.3 
(d, C, J = 58.6, C1), 129.2 (d, CH, J = 11.5, C3), 59.8 (B) and 58.8 (A) 
(C,ProH), 57.8 (A) and 56.2 (B) (CCysH), 52.4 (B) and 52.1 (A) (OCH3), 
46.9 (A) and 46.3 (B) (C,ProH2), 30.8 (B) and 30.1 (A) (C,CysH2), 29.7 (A) 
and 28.9 (B) (C,ProH2), 28.4 (CBocH3,) and 24.8 (A) and 22.5 (B) (C,ProH2). 
31P NMR (CDCl3, 300 MHz,  (ppm)): 37.0. MS ESI(+) m/z: [M+H]+ = 
791.2 (calcd), 791,1 (found). Elemental analysis found (%): C, 48.64; H, 
4.86; N, 3.55; S, 4.08; calcd. for C32H38AuN2O5PS:  C, 48.61; H, 4.84; N, 
3.54; S, 4.06. IR(cm-1): 3292 (br, OCONH), 1739 (s, COOMe), 1703 (s, 
OCONH), 1640 (s, CONH), 1480 and 1434 (w, Ar), 1161 and 1099 (s, C-
O) and 746, 709 and 691 (w, Ar). TLC Rf: 0.5 (AcOEt/hexane 1:1). 
Boc-Cys(AuPPh2Py)-Gly-OMe (7): The reaction of 1b (0.196 g, 0.67 
mmol), [AuCl(PPh2Py)] (0.332 g, 0.67 mmol) and K2CO3 (0.370 g, 2.7 
mmol) following the Procedure C, afforded 7 (0.484 g, 0.64 mmol) as a 
white solid (Yield = 96.2 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
8.76 (d, 1H, J = 4.5, H1), 8.02 (“t”, 1H, J = 7.5, H4), 7.80 (m, 1H, H3), 
7.71 and 7.47 (m, 10H, Ar), 7.43 (m, 1H, CONHGly), 7.37 (m, 1H, H2), 
5.91 (m, 1H, CONHCys), 4.40 (m, 1H, C,CysH), 3.96 and 3.84 (dd, ABX 
system, 2H, diastereotopic protons, J = 21.6 and 5.4 and J = 18.3 and 
4.8, C,GlyH2), 3.65 (s, 3H, OCH3), 3.65 and 3.26 (m and dd, ABM system, 
2H, diastereotopic protons, J = 12.3 and 6.6, C,CysH2) and 1.42 (s, 9H, 
CBocH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 171.7 (COOMe), 
169.9 (CONHGly), 155.4 (CONHCys), 154.3 (CH, C5), 151.2 (d, CH, J = 
14.9, C1), 136.6 (d, CH, J = 11.0, C3), 134.6 (d, CH, J = 13.7, C7), 131.7 
(d, CH, J = 32.8, C4), 131.6 (d, CH, J = 2.4, C9), 129.7 (C, C6), 129.5 (d, 
CH, J = 11.5, C8), 125.1 (d, CH, J = 2.3, C2), 79.8 (C, CBoc), 58.0 
(C,CysH), 52.1 (OCH3), 41.2 (C,GlyH2), 30.8 (C,CysH2) and 28.3 (CBocH3). 
31P NMR (CDCl3, 300 MHz,  (ppm)): 37.0. HRMS ESI(+) m/z: [M+Na]+ = 
774.1436 (calcd), 774.1460 (found). Elemental analysis found (%): C, 
44.67; H, 4.46; N, 5.55; S, 4.09; calcd. for C28H33AuN3O5PS:  C, 44.75; H, 
4.43; N, 5.59; S, 4.27. IR (cm-1): 3316 (br, CONH and OCONH), 1747 (s, 
COOMe), 1705 (s, OCONH), 1667 (s, CONH), 1570, 1480 and 1435 (w, 
Ar), 1159 and 1099 (s, C-O) and 746, 709 and 691 (w, Ar). TLC Rf: 0.5 
(AcOEt/hexane 1:1). 
(HCl·H-Cys-Gly-OMe)2 (8a): To a 3 N HCl/AcOEt solution (30 ml) 1a 
(1.025 g, 1.76 mmol) was added. The mixture was stirred for 24 h at 
room temperature. Then, the white precipitate was filtered off and dried, 
affording 8a (0.689 g, 1.51 mmol) as a white solid (Yield = 86.0%). This 
reaction can also be carried out employing TFA/CH2Cl2 (1:1 v/v). 1H NMR 
(D2O, 400 MHz, (ppm), J (Hz)): 4.37 (dd, 2H, J = 10.4 and 6.8, C,CysH), 
4.01 (d, 4H, J = 2.4, C,GlyH2), 3.67 (s, 6H, OCH3), 3.33 and 3,14 (dd, 
ABM system, 4H, diastereotopic protons, J = 20.0 and 6.8 and J = 20.0 
and 6.4, C,CysH2). 13C NMR (D2O, 400 MHz,  (ppm), J (Hz)): 171.6 
(COOMe), 168.6 (CONHGly), 52.9 (C,CysH), 51.8 (OCH3), 41.3 (C,GlyH2) 
and 37.4 (C,CysH2). HRMS ESI(+) m/z: [M-Cl]+ = 419.0820 (calcd), 






419.1018 (found). IR (cm-1): 3300-3100 (br, NH3), 3196 (br, CONH), 1734 
(s, COOMe), 1675 (s, CONH), 1211 (s, C-O).  
(Z-Cys-Gly-OMe)2 (8b): To a solution of 8a (1.366 g, 3 mmol) in CH2Cl2 
(12 ml) were added DIPEA (2.36 ml, 13.8 mmol), DMAP (cat.) and benzyl 
chloroformate (1.11 ml, 7.8 mmol) dropwise and at 0º C. Then, the 
mixture was stirred at room temperature overnight. The reaction was 
following by TLC until the reaction was completed and the solvent 
evaporated under reduced pressure. The crude was redissolved in 
AcOEt (50 ml) and washed with water (3 x 50 ml). The organic phases 
were collected and dried over anhydrous MgSO4, filtered off and 
evaporated to dryness. The crude of the reaction was purified by column 
chromatography on silicagel using as eluyent a mixture of AcOEt/hexane 
(8:2) to give 8b (0.787 g, 1.21 mmol) as a white solid (Yield = 40.4 %). 1H 
NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 7.96 (“t”, 2H, J = 5.4, CONHGly), 
7.34 (m, 10H, Ar), 5.81 (d, 2H, J = 9.3, CONHCys), 5.17 (s, 4H, 
diastereotopic protons, CBn,CysH2), 5.08 (m, 2H, C,CysH), 4.07 and 3.91 
(dd, ABX system, 4H, diastereotopic protons, J = 18.0 and 5.7 and J = 
18.0 and 5.1, C,GlyH2), 3.73 (s, 6H, OCH3), 3.05 and 2.91 (dd, ABM 
system, 4H, diastereotopic protons, J = 14.7 and 3.9 and J = 14.4 and 
10.5, C,CysH2). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 170.4 
(COOMe), 169.7 (CONHGly), 156.6 (CONHCys), 136.2 (C, C1Ar), 128.6 
(CH, C3Ar), 128.2 (CH, C4Ar), 127.6 (CH, C2Ar), 67.4 (CBnH2), 54.8 
(C,CysH), 52.3 (OCH3), 46.4 (C,GlyH2) and 41.2 (C,CysH2). ESI(+) m/z: 
[M+Na] + = 673.1 (calcd), 673.0 (found). IR (cm-1): 3314 (br, CONH and 
OCONH), 1750 (s, COOMe), 1688 (s, OCONH), 1645 (s, CONH), 1523 
and 1436 (w, Ar), 1109 and 1042 (s, C-O), 732 and 696 (w, Ar), 639 (s, 
S-S). TLC Rf: 0,3 (AcOEt/hexane 1:1). 
Z-Cys-Gly-OMe (8c): The reaction of 8b (0.760 g, 1.17 mmol), -
mercaptoethanol (0.328 ml, 4.68 mmol) and DIPEA (0.801 ml, 4.68 
mmol) following the Procedure B, afforded 8c (0.225 g, 0.69 mmol) as a 
white solid (Yield = 29.6 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
7.35 (m, 5H, Ar), 6.80 (m, 1H, CONHGly), 5.78 (d, 1H, J = 6.9, CONHCys), 
5.14 (s, 2H, CBn,CysH2), 4.48 (m, 1H, C,CysH), 4.08 and 4.00 (dd, ABX 
system, 2H, diastereotopic protons, J = 19.5 and 5.7 and J = 18.6 and 
5.4, C,GlyH2), 3.75 (s, 3H, OCH3), 3.15 and 2.73 (ddd, ABMN system, 2H, 
diastereotopic protons, J = 13.9, 7.5 and 4.2 and J = 14.0, 10.6 and 6.1, 
C,CysH2) and 1.70 (dd, J = 10.5 and 7.5, SH). 13C NMR (CDCl3, 300 MHz, 
 (ppm), J (Hz)): 170.0 (COOMe), 169.8 (CONHGly), 156.0 (CONHCys), 
135.8 (C, C1Ar), 128.6 (CH, C3Ar), 128.4 (CH, C4Ar), 128.2 (CH, C2Ar), 
67.5 (CBnH2), 55.8 (C,CysH), 52.4 (OCH3), 41.2 (C,GlyH2) and 27.0 
(C,CysH2). HRMS ESI(+) m/z: [M+Na]+ = 349.0828 (calcd), 349.0829 
(found). IR (cm-1): 3277 (br, CONH and OCONH), 2579 (w, SH), 1744 (s, 
COOMe), 1687 (s, OCONH), 1654 (s, CONH), 1533, 1464 and 1435 (w, 
Ar), 1108 (s, C-O), 799, 761 and 699 (w, Ar). TLC Rf: 0.5 
(acetone/hexane 1:1). 
Z-Cys(AuPPh3)-Gly-OMe (8): The reaction of 8c (0.187 g, 0.57 mmol), 
[AuCl(PPh3)] (0.284 g, 0.57 mmol) and K2CO3 (0.314 g, 2.3 mmol) 
following the Procedure C, afforded 8 (0.282 g, 0.47 mmol) as a white 
solid (Yield = 82.4 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 7.41 
(m, 20H, ArPhe and Ar), 7.40 (m, 1H, CONHGly), 6.18 (d, 1H, J = 6.0, 
CONHCys), 5.13 and 5.04 (d, AB system, 2H, diastereotopic system, J = 
12.6 and J = 12.3, CBn,CysH2), 4.44 (dd, 1H, J = 10.5 and 6.0, C,CysH), 
3.93 and 3.81 (dd, ABX system, 2H, diastereotopic protons, J = 18.3 and 
5.1 and J = 18.3 and 4.5, C,GlyH2), 3.66 (s, 3H, OCH3), 3.63 and 3.25 (m 
and dd, ABM system, 2H, diastereotopic protons, J = 16.2 and 6.9, 
C,CysH2). 31P NMR (CDCl3, 300 MHz, (ppm), J (Hz)): 37.9. 13C NMR 
(CDCl3, 300 MHz,  (ppm), J (Hz)): 171.3 (COOMe), 169.9 (CONHGly), 
156.1 (CONHCys), 136.4 (C, C1Ar), 134.2 (d, CH, J = 13.8, C6Ar,PPh3), 
131.6 (d, CH, J = 2.4, C8Ar,PPh3), 129.4 (d, C, J = 57.0 C5Ar,PPh3), 129.2 (d, 
CH, J = 11.5, C7Ar,PPh3), 128.5 (CH, C3Ar), 128.0 (CH, C4Ar), 127.9 (CH, 
C2Ar), 66.9 (CBn,CysH2), 58.4 (C,CysH), 52.2 (OCH3), 41.2 (C,GlyH2) and 
30.7 (C,CysH2). HRMS ESI(+) m/z: [M+H]+ = 785.1507 (calcd), 785.1534 
(found). Elemental analysis found (%): C, 48.68; H, 4.36; N, 3.55; S, 
4.29; calcd. for C32H32AuN2O5PS: C, 48.99; H, 4.11; N, 3.57; S, 4.09. IR 
(cm-1): 3329 (br, CONH and OCONH), 1716 (s, COOMe), 1667 (s, CONH 
and OCONH), 1496, 1480 and 1434 (w, Ar), 1206 and 1099 (s, C-O), 
743, 709 and 690 (w, Ar). TLC Rf: 0.5 (AcOEt/hexane 1:1). 
(Boc-Cys-Oic-OMe)2 (9a): The reaction of (Boc-Cys-OH)2 (0.220 g, 0.5 
mmol), HCl·H-Oic-OMe (0.241 g, 1.1 mmol), PyBOP (0.572 g, 1.1 mmol) 
and DIPEA (0.548 ml, 3.2 mmol) in anhydrous DMF (15 ml) following the 
Procedure A, afforded 9a (0.640 g, 0.98 mmol) as a white solid (Yield = 
97.8 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)):  rotamers mixture 
(ratio 1:0.3) : 5.27 (B) and 5.15 (A) (m and d, 2H, J = 6.0, CONHCys), 4.76 
(m, 2H, C,CysH), 4.54 (B) and 4.44 (A) (m and dd, 2H, J = 10.2 and 8.1, 
C,OicH), 4.22 (m, 2H, C,OicH), 3.79 (B) and 3.74 (A) (s, 6H, OCH3), 3.07 
and 2,87 (dd, ABM system, 4H, diastereotopic protons, J = 14.1 and 4.2 
and J = 13.8 and 9.3, C,CysH2), 2.42 (m, 2H, C,OicH), 2.16 and 2.01 (m, 
4H, diastereotopic protons, C,OicH2), 1.71 and 1.36 (m, 16H, C5OicH2, 
C6OicH2, C7OicH2 and C8OicH2), 1.44 (s, 18H, CBocH3). 13C NMR (CDCl3, 
300 MHz,  (ppm), J (Hz)): rotamers mixture : 173.2 (B) and 172.5 (A) 
(COOMe), 170.2 (B) and 169.7 (A) (CONOic), 155.4 (CONHCys), 80.0 (C, 
CBoc), 59.1 (A) and 58.8 (B) (COicH), 58.1 (B) and 58.0 (A) (C,OicH), 52.9 
(B) and 52.2 (A) (OCH3), 51.0 (C,CysH), 42.0 (CCysH2), 37.8 (B) and 
37.5 (A) (C,OicH), 30.6 (B) and 30.4 (A) (C,OicH2), 28.3 (CBocH3) and 28.7, 
25.5, 23.7 and 19.8 (C5OicH2, C6OicH2, C7OicH2 and C8OicH2). ESI(+) m/z: 
[M+H]+ = 771.3 (calcd), 771.2 (found). IR (cm-1): 3386 (br, OCONH), 
1747 (s, COOMe), 1705 (s, OCONH), 1634 (s, CON), 1165 and 1016 (s, 
C-O), 638 (w, S-S). TLC Rf: 0.4 (AcOEt/hexane 1:1). 
Boc-Cys-Oic-OMe (9b): The reaction of 9a (0.610 g, 0.79 mmol), -
mercaptoethanol (0.224 ml, 3.2 mmol) and DIPEA (0.548 ml, 3.2 mmol) 
following the Procedure B, afforded 9b (0.417 g, 1.08 mmol) as a white 
solid (Yield = 68.3 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 5.19 
(d, 1H, J = 9.6, CONHCys), 4.58 (dd, 1H, J = 15.6 and 6.4, C,CysH), 4.47 
(dd, 1H, J = 10.3 and 8.2, C,OicH), 4.11 (m, 1H, C,OicH), 3.74 (s, 3H, 
OCH3), 2.90 and 2.71 (ddd and m, ABMN system, 2H, diastereotopic 
protons, J = 13.6, 8.2 and 7.1, C,CysH2), 2.41 and 2.20 (m, 2H, 
diastereotopic protons, C,OicH2), 2.08 (m, 1H, C,OicH), ), 1.70 (dd, 1H, J 
= 9.0, SH), 1.62 and 1.33 (m, 8H, C5OicH2, C6OicH2, C7OicH2 and C8OicH2), 
1.70 (dd, 1H, J = 9.0, SH)  1.44 (s, 9H, CBocH3). 13C NMR (CDCl3, 300 
MHz,  (ppm), J (Hz)): 172.5 (COOMe), 169.5 (CONOic), 155.4 
(CONHCys), 80.0 (C, CBoc), 58,7 (C,OicH), 58,3 (C,OicH), 53.4 (C,CysH), 
52.2 (OCH3), 37.7 (C,OicH), 30.3 (C,CysH2), 29.0 (C,OicH2), 28.3 (CBocH3) 
and 28.0, 25.6, 23.7 and 19.9 (C5OicH2, C6OicH2, C7OicH2 and C8OicH2). 
MS ESI(+) m/z: [M+H]+ = 387.2 (calcd), 387.1 (found). IR (cm-1): 3285 (br, 
OCONH), 2554 (w, SH), 1745 (s, COOMe), 1702 (s, OCONH), 1630 (s, 
CON), 1163 and 1098 (s, C-O). TLC Rf: 0.6 (acetone/hexane 1:1). 
Boc-Cys(AuPPh3)-Oic-OMe (9): The reaction of 9b (0.356 g, 0.92 
mmol), [AuCl(PPh3)] (0.456 g, 0.92 mmol) and K2CO3 (0.507 g, 3.7 
mmol) following the Procedure C, afforded 9 (0.731 g, 0.86 mmol) as a 
white solid (Yield = 94.0 %). 1H NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 
rotamers mixture (ratio 1 : 0.2) : 7.50 (m, 15H, Ar), 5.27 (B) and 5.13 (A) 
(d, 1H, J = 6.6 and 8.4, CONHCys), 4.43 (dd, 1H, J = 10.2 and 7.8, 
C,OicH), 4.34 (m, 1H, C,CysH), 4.12 (m, 1H, COicH), 3.73 (B) and 3.68 
(A) (s, 3H, OCH3), 3.34 and 3.13 (dd, ABM system, 2H, diastereotopic 
protons, J = 13.5 and 3.3, C,CysH2), 2.40 (m, 1H, C,OicH), 2.01 (m, 2H, 
C,OicH2), 1.52 (m, 8H, C5OicH2, C6OicH2, C7OicH2 and C8OicH2) and 1.32 (s, 
9H, CBocH3). 13C NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): rotamers 
mixture: 172.9 (COOMe), 171.1 (CONOic), 156.0 (CONHCys), 134.2 (d, CH, 
J = 13.7, C2), 131.8 (d, CH, J = 2.5, C4), 129.2 (d, CH, J = 11.7, C3), 
129.1 (d, C, J = 59.2, C1), 79.1 (C, CBoc), 59.5 (B) and 58.7 (A) (C,OicH), 
58.1 (B) and 57.9 (A) (C,CysH), 57.7 (B) and 57.6 (A) (C,OicH), 52.2 (B) 
and 52.0 (A) (OCH3), 37.5 (A) and 37.4 (A) (C,OicH), 30.4 (C,CysH2), 29.1 






(C,OicH2), 28.3 (CBocH3) and 29.1, 25.5, 23.6 and 19.9 (C5OicH2, C6OicH2, 
C7OicH2 and C8OicH2). 31P NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 36.4. 
HRMS ESI(+) m/z: [M+H]+ = 845.2446 (calcd), 845.2601 (found). 
Elemental analysis found (%): C, 51.32; H, 5.37; N, 3.45; S, 4.29; calcd. 
for C36H44AuN2O5PS: C, 51.18; H, 5.25; N, 3.32; S, 3.80. IR (cm-1): 3279 
(br, OCONH), 1746 (s, COOMe), 1702 (s, OCONH), 1637 (s, CON), 
1480 and 1434 (w, Ar), 1165 and 1099 (s, C-O), 745 and 691 (estrecha, 
Ar). TLC Rf: 0.5 (AcOEt/hexane1:1). 
[Boc-Cys(AuPPh3)2-Gly-OMe]OTf (10): To a solution of the complex 1 
(0.072 g, 0.1 mmol) in CH2Cl2 (5 ml) was added [Au(OTf)(PPh3)] (0.061 g, 
0.1 mmol) freshly prepared. The mixture was stirred for 2 h at room 
temperature. Then, the yellow solution resultant was filtered on Celite. 
The solution was concentrated to ca. 5 ml and addition of hexane (20 ml) 
afforded 10 as an orange solid (0.122 g, 0,09 mmol), (yield = 90.0 %). 1H 
NMR (CDCl3, 300 MHz,  (ppm), J (Hz)): 7.99 (“t”, 1H, CONHGly), 7.42 (m, 
30H, Ar), 6.36 (m, 1H, CONHCys), 4.58 (“dt”, 1H, J = 7.1 and 4.6, C,CysH), 
4.01 and 3,90 (dd, ABM system, 2H, diastereotopic protons, J = 13.2 and 
4.5 and J = 12.9 and 6.9, C,CysH2), 3.79 (d, 2H, J = 5.7, CGlyH2), 3.58 (s, 
3H, OCH3) and 1.25 (s, 9H, CBocH3). 13C NMR (CDCl3, 300 MHz,  (ppm), 
J (Hz)): 170.4 (COOMe), 169.6 (CONHGly), 155.6 (CONHCys), 134.1 (d, 
CH, J = 13.7, C2), 132.2 (d, CH, J = 2.5, C4), 129.4 (d, CH, J = 11.9, C3), 
128.0 (d, C, J = 60.8, C1), 120.6 (d, C, J = 320.3, CF3), 80.0 (C, CBoc), 
57.5 (C,CysH), 51.9 (OCH3), 41.2 (C,GlyH2), 34.0 (C,CysH2) and 28.1 
(CH3,Boc). 31P NMR (CDCl3, 300 MHz,  (ppm)): 33.8. 19F NMR (CDCl3, 
300 MHz,  (ppm)): -77.85. HRMS ESI(+) m/z: [M]+ = 1209.2162 (calcd), 
1209.2504 (found). Elemental analysis found (%): C, 42.31; H, 3.39; N, 
2.09; S, 4.47; calcd. for C48H49Au2F3N2O8P2S2: C, 42.42; H, 3.63; N, 
2.06; S, 4.72. IR (cm-1): 3316 (br, CONH and OCONH), 1751 (s, 
COOMe), 1709 (s, OCONH), 1673 (s, CONH), 1480 and 1436 (w, Ar), 
1100 and 1027 (s, C-O), 744 and 690 (w, Ar).  
[Boc-Cys(AuPPh3)3-Gly-OMe](OTf)2 (11): To a solution of complex 1 
(0.072 g, 0.1 mmol) in CH2Cl2 (5 ml) was added [Au(OTf)(PPh3)] (0.122 g, 
0.2 mmol) freshly prepared. The mixture was stirred for 2 h at room 
temperature. Then, the yellow solution resultant was filtered on Celite. 
The solution was concentrated to ca. 5 ml and addition of hexane (20 ml) 
afforded 11 as an orange solid (0.172 g, 0.09 mmol), (yield = 87 %). 1H 
NMR (CDCl3, 300 MHz, (ppm), J (Hz)): rotamers mixture (ratio 1:0.3) 
8.42 (B) and 8.02 (A) (t and t, 1H, J = 5.4 and J = 5.4, CONHGly), 7.49-
7.38 (m, 45H, Ar), 6.27 (A) and 5.26 (B) (d and m, 1H, J = 6.0, CONHCys), 
4.63 (A) and 4.13 (B) (c and m, 1H, J = 3.9, C,CysH), 4.00 and 3.91 (dd, 
ABM system, 2H, diastereotopic protons, J = 13.2 and 4.2 and J = 12.9 
and 6.9, C,CysH2), 3.78 (A) and 3.72 (B) (d and m, 2H, J = 5.7, C,GlyH2), 
3.53 (A) and 3.36 (B) (s, 3H, OCH3) and 1.21 (s, 9H, CBocH3). 13C NMR 
(CDCl3, 400 MHz,  (ppm), J (Hz)): 170.2 (B) and 169.6 (A) (COOMe), 
169.5 (B) and 169.1 (A) (CONHGly), 155.4 (CONHCys), 139.9 (d, CH, J = 
13.7, C2), 132.3 (CH, C4), 129.4 (d, CH, J = 12.0, C3), 127.4 (d, C, J = 
62.6, C1), 120.5 (d, C, J = 320.4, CF3), 80.0 (C, CBoc), 58.5 (A) and 57.1 
(B) (C,CysH), 51.8 (A) and 51.7 (B) (OCH3), 41.1 (C,GlyH2), 34.2 (A) and 
33.5 (B) (C,CysH2) and 28.0 (A) and 27.4 (B) (CH3,Boc). 31P NMR (CDCl3, 
300 MHz,  (ppm)): 32.3. 19F NMR (CDCl3, 300 MHz,  (ppm)): -77.8. 
HRMS ESI(+) m/z: [M-AuPPh3]+ = 1209.2162 (calcd), 1209.2231 (found). 
Elemental analysis found (%): C, 39.31; H, 3.38; N, 1.08; S, 6.43; calcd. 
for C48H48Au2F6NO10P2S3: C, 39.35; H, 3.30; N, 0.96; S, 6.57. IR (cm-1): 
3316 (br, CONH and OCONH), 1751 (s, COOMe), 1709 (s, OCONH), 
1673 (s, CONH), 1480 and 1436 (w, Ar), 1100 and 1027 (s, C-O), 744 
and 690 (w, Ar).  
Cell culture: Jurkat (leukaemia) and MiaPaca2 (pancreatic carcinoma) 
cell lines were maintained in RPMI 1640, while A549 (lung carcinoma) 
were grown in DMEM (Dulbecco´s Modified Eagle´s Medium). Both 
media were supplemented with 5% fetal bovine serum (FBS), 200 U/ml 
penicillin, 100 g/ml streptomycin and 2 mM L-glutamine. Medium for 
A549 cells was also supplemented with 2.2 g/l Na2CO3, 100 g/ml 
piruvate and 5 ml non-essential amino acids (Invitrogen).  Cultures were 
maintained in a humidified atmosphere of 95% air/5% CO2 at 37 ºC. 
Adherent cells were allowed to attach for 24 h prior to addition of 
compounds.  
Cytotoxicity assay by MTT: The MTT assay was used to determine cell 
viability as an indicator for cells sensitivity to the complexes. 
Exponentially growing cells were seeded at a density of approximately 
1x105 cells/ml for the adherent cell lines (A549, MiaPaca2) or 5x104 
cells/ml (Jurkat), in a 96-well flat-bottomed microplate and 24 h later they 
were incubated for 24 h with the compounds. The complexes were 
dissolved in DMSO and tested in concentrations ranging from 0.1 to 25 
M and in quadruplicate. Cells were incubated with our compounds for 
24 h at 37 ºC. 10 l of MTT (5 mg/ml) was added and plates were 
incubated for 1-3 h at 37 ºC. Finally, 100 µl/well iPrOH (0.05 M HCl) was 
added. The optical density was measured at 490 nm using a 96-well 
multiscanner autoreader (ELISA). The IC50 was calculated by non-linear 
regression analysis using Origin software (Origin Software, Electronic 
Arts, Redwood City, California, USA). 
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